← Back to Clinical Trials
Recruiting Phase 2, Phase 3 NCT06798363
Efficacy and Safety of Different Initial Doses of Oral Propranolol in the Treatment of Ulcerated Infantile Hemangioma
Trial Parameters
Condition Infantile Hemangioma
Sponsor West China Hospital
Study Type INTERVENTIONAL
Phase Phase 2, Phase 3
Enrollment 40
Sex ALL
Min Age 1 Month
Max Age 4 Years
Start Date 2025-05-02
Completion 2026-06-30
Interventions
propranolol
Brief Summary
The main objective of this study was to determine the efficacy of different doses of propranolol in the treatment of ulcerattion infantile hemangioma (IH).
Eligibility Criteria
Inclusion Criteria: 1. all patients with ulcer IH; 2. children with ulcer IH treated with propranolol. Exclusion Criteria: 1\) children with ulcer IH who received other therapeutic interventions were excluded; 2) Children whose families refused to participate in the study; 3) patients with contraindications to oral propranolol, such as allergy to propranolol, severe bradycardia and bronchial asthma; 4) children lost to follow-up during oral propranolol treatment; 5) children unable to oral propranolol or continue to oral propranolol due to other reasons. \-